JAK inhibitors in rheumatoid arthritis

JAK inhibitors in rheumatoid arthritis

Bibliografski detalji
Glavni autor:	Taylor, PC
Format:	Journal article
Jezik:	English
Izdano:	Springer Nature 2019

Slični predmeti

JAK Inhibitors in Rheumatoid Arthritis
od: Kathryn Biddle, i dr.
Izdano: (2022-08-01)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
od: Taylor, P
Izdano: (2019)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
od: Taylor, PC, i dr.
Izdano: (2023)

Pain in rheumatoid arthritis - Could JAK inhibition be the answer?
od: Mehta, P, i dr.
Izdano: (2020)

JAK inhibitors for the treatment of rheumatoid arthritis
od: Akio Morinobu
Izdano: (2020-10-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
od: Vishal R. Tandon, i dr.
Izdano: (2022-07-01)

The Jak/STAT pathway: a focus on pain in rheumatoid arthritis
od: Simon, LS, i dr.
Izdano: (2020)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
od: Rita A. Moura, i dr.
Izdano: (2021-02-01)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
od: Cutolo M, i dr.
Izdano: (2013-11-01)

JAK ACADEMY in Rheumatoid Arthritis (RA)
od: Roberto Caporali, i dr.
Izdano: (2018-09-01)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
od: Jacopo Angelini, i dr.
Izdano: (2020-07-01)

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis
od: Maurizio Benucci, i dr.
Izdano: (2023-08-01)

New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors
od: Masaru Kato
Izdano: (2020-04-01)

Editor’s Pick: JAK Inhibitors in the Treatment Algorithm of Rheumatoid Arthritis: A Review
od: Salvatore Bellinvia, i dr.
Izdano: (2018-07-01)

Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis
od: Karina Rossi Bonfiglioli, i dr.
Izdano: (2021-11-01)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
od: Harrington R, i dr.
Izdano: (2020-09-01)

The rheumatoid arthritis impact of disease (RAID) score in telemedicine management of rheumatoid arthritis
od: Taylor, PC
Izdano: (2024)

Aetiopathology of rheumatoid arthritis
od: Taylor, PC, i dr.
Izdano: (2022)

Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment
od: Xuyang Xia, i dr.
Izdano: (2025-03-01)

Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
od: Zhang N, i dr.
Izdano: (2021-05-01)

Emerging Insights: The Impact of Real-world Evidence on Rheumatoid Arthritis. Latest Evidence from Janus Kinase (JAK) Inhibitors
od: Peter Taylor
Izdano: (2024-01-01)

Aetiopathology of rheumatoid arthritis
od: Taylor, PC, i dr.
Izdano: (2018)

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry
od: Yoshiya Tanaka, i dr.
Izdano: (2025-01-01)

Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis
od: Hani M. Almoallim, i dr.
Izdano: (2025-01-01)

JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission
od: Jing Luo, i dr.
Izdano: (2024-07-01)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
od: Irma Convertino, i dr.
Izdano: (2023-03-01)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
od: Soo-Kyung Cho, i dr.
Izdano: (2023-07-01)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
od: Shuhei Yoshida, i dr.
Izdano: (2023-10-01)

One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis
od: Lu Xiao, i dr.
Izdano: (2022-09-01)

Towards better personalised care in rheumatoid arthritis
od: Taylor, PC
Izdano: (2025)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
od: Małgorzata Wisłowska
Izdano: (2024-11-01)

A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
od: Rioko Migita, i dr.
Izdano: (2022-01-01)

Non-Invasive Assessment of Micro- and Macrovascular Function after Initiation of JAK Inhibitors in Patients with Rheumatoid Arthritis
od: Panagiota Anyfanti, i dr.
Izdano: (2024-04-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study
od: Małgorzata Wisłowska
Izdano: (2022-05-01)

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
od: Taylor, P, i dr.
Izdano: (2018)

JAK inhibitors in systemic juvenile idiopathic arthritis
od: Tingyan He, i dr.
Izdano: (2023-04-01)

The opportunities and challenges of telemedicine in the management of people with rheumatoid arthritis
od: Taylor, PC
Izdano: (2022)

Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
od: Se Rim Choi, i dr.
Izdano: (2023-07-01)

Treating-to-target or treating the patient in rheumatoid arthritis?
od: Taylor, PC, i dr.
Izdano: (2019)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
od: Taylor, P, i dr.
Izdano: (2019)